Zila to Launch ViziLite(R) Plus with TBlue630(TM) at Annual ADA Meeting
October 05 2005 - 6:30AM
Business Wire
Zila Pharmaceuticals, Inc., a business unit of Zila, Inc.
(Nasdaq:ZILA), will launch its ViziLite(R) Plus with TBlue630(TM)
oral lesion identification and marking system at the 146th American
Dental Association Annual Session in Philadelphia, October 6 to 9,
2005. ViziLite(R) Plus combines the oral screening technology of
ViziLite(R), an advanced chemiluminescent light technology to help
detect oral abnormalities, with TBlue630, a marking system using
Zila(R) Tolonium Chloride (ZTC(TM)), the only patented
pharmaceutical-grade form of toluidine blue that has been cleared
by the FDA for use in marking lesions identified during a
ViziLite(R) examination. ViziLite(R) Plus makes oral screening more
comprehensive than ever before and is indicated for use in
individuals at increased risk of oral cancer: if ViziLite(R)
reveals an abnormality, TBlue630 can then be used to mark
suspicious lesions for further evaluation. Douglas D. Burkett,
Ph.D., Zila's Chairman, President and CEO, stated, "The launch of
ViziLite(R) Plus with TBlue630 is an important milestone in the
fight against oral cancer. The use of Zila(R) Tolonium Chloride in
this new system provides the practitioner with an opportunity to
further evaluate and monitor lesions after they are identified
during a ViziLite(R) examination. ViziLite(R) Plus helps dental
professionals perform a complete and thorough oral screening, and
we all recognize that better screening saves lives. We are pleased
that with the recent addition of Sullivan-Schein Dental, all major
dental distributors in the U.S. are now promoting ViziLite(R)."
Zila Pharmaceuticals will supply ViziLite(R) Plus in product
configurations of twenty ViziLite(R) exam kits with two TBlue630
marking systems, and forty ViziLite(R) exam kits with four TBlue630
marking systems. A supplemental product configuration comprised
primarily of TBlue630 marking systems will also be available to
those that have previously purchased ViziLite(R) Plus. Shipping of
ViziLite(R) Plus will begin on a limited basis after the ADA launch
primarily to opinion leaders, with general distribution to follow
shortly thereafter. In addition to launching ViziLite(R) Plus with
TBlue630 at the ADA annual meeting, several other important
activities will take place. For the first time, ViziLite(R) will be
included by the ADA as a part of the health screening service being
provided to all dental professionals in attendance at the event.
Free ViziLite(R) screening exams will be performed all day on
Saturday, October 8, 2005 in the Philadelphia Marriott Hotel. Zila
Pharmaceuticals will also announce the details of an agreement with
the ADA Foundation to fund programs to increase the awareness of
oral cancer among the ADA membership in 2006 and beyond. In
attendance at the announcement, scheduled for October 9 at the
Philadelphia Marriott Hotel, will be Zila executives, ADA
Foundation executives, and several members of the newly appointed
Zila Dental Advisory Board. The new Zila Dental Advisory Board is a
group of dental professionals that will advise the company on
issues related to advancing the message of oral screening in
dentistry, to include consulting with the company on marketing and
sales issues, and providing input on the design and implementation
of clinical trials. The members of the Zila Dental Advisory Board
are: -- David Sirois, DMD, Ph.D. from the New York University
College of Dentistry; -- Joel Epstein, DDS, MSD, FRCD from the
College of Medicine, Chicago Cancer Center; -- Sol Silverman, Jr.,
DDS, MS from University of California at San Francisco
Comprehensive Cancer Center; -- Angelo Mariotti, DDS, Ph.D, from
The Ohio State University College of Dentistry; -- Lawrence Meskin,
DDS, Ph.D., from Colorado University School of Dentistry; and --
Jill Rethman, RDH, BA, Dental Consultant and Speaker from Kaneohe,
Hawaii. "We are pleased and honored to be working with these
leaders in the field of dentistry as well as the ADA Foundation as
we continue to grow our products and technologies to detect
pre-cancer and cancer at the earliest possible stage in order to
save lives," stated Dr. Burkett. About Oral Cancer: According to
the Oral Cancer Foundation, approximately 30,000 new oral cavity
and pharyngeal cancers are being diagnosed each year in the U.S.,
resulting in the death of approximately 50% of the people affected
within five years. Oral cancer remains one of the most debilitating
and disfiguring of all malignancies. In most people diagnosed with
oral cancer, the disease has metastasized, resulting in a poor
prognosis because the usual method of detecting the disease is a
visual examination that only results in the identification of early
cancers 35% of the time. Those who do survive frequently undergo
disfiguring surgery. When oral cancer is detected early, survival
rates are about 80%; detected late, the survival rate reportedly
falls to 20%. About Zila Tolonium Chloride: Zila(R) Tolonium
Chloride (ZTC(TM)) is a patented composition of matter that is
designed to be superior to traditional toluidine blue. ZTC(TM) is
the ingredient in the recently FDA cleared TBlue630 and is also the
active ingredient in OraTest(R) which is progressing through the
regulatory process with the FDA. Zila now has nine issued United
States patents related to ZTC(TM) and/or the OraTest(R) product
with expiration dates ranging from 2011 to 2020. An additional 34
corresponding foreign patents have been issued, including European
patents covering 15 additional countries, and there are pending
United States and international applications that would result in
coverage of ZTC(TM) and/or OraTest(R) related technology by over
250 United States and foreign patents. These patents and pending
applications cover: (i) the composition of matter for ZTC(TM); (ii)
the process for manufacturing ZTC(TM); (iii) the mechanism of
action, methods and products for using ZTC(TM) to detect epithelial
cancer; (iv) utilizing ZTC(TM) or related technology to mark
lesions identified by optimized wavelength light and (v) other
compounds that are chemically related to Tolonium Chloride for use
in detecting epithelial cancer. About Zila Zila, Inc.,
headquartered in Phoenix, is an innovator in preventative
healthcare technologies and products, focusing on enhanced body
defense and the detection of pre-disease states. Zila, Inc. has
three business units: Zila Biotechnology, Inc., a research,
development and licensing business specializing in
pre-cancer/cancer detection through its patented ZTC(TM) and
OraTest(R) technologies. Zila Pharmaceuticals, Inc., marketer of
products to promote oral health and prevent oral disease, including
ViziLite(R) Plus oral examination kits and Peridex(R) prescription
periodontal rinse. Zila Nutraceuticals, Inc., manufacturer and
marketer of Ester-C(R) and Ester-E(R), branded, highly effective
forms of Advanced Protection vitamins C and E. For more information
about Zila, Inc. visit www.zila.com. This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based largely on
Zila's expectations or forecasts of future events, can be affected
by inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely impact revenues, profitability,
cash flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Form 10-K for its
fiscal year ended July 31, 2004, and its Form 10-Q for the quarter
ended April 30, 2005, filed with the Securities and Exchange
Commission.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024